OS Therapies Incorporated

OSTX

US68764Y2072

Biotechnology & Medical Research

Market Closed - Nyse Other stock markets 16:00:00 2024-09-18 EDT			5-day change	1st Jan Change
3.520 ^USD	-0.28%		+0.28%	0.00%

09-13	OS Therapies to Develop Two Novel Cancer Treatment Candidates	MT
09-13	OS Therapies Announces Development of Two Novel Tunable Antibody Drug Conjugate-Based Therapeutic Candidates	CI

Presenter SpeechUnknown Attendee (Attendees)Hello. We're here with Motti Farbstein, Chief Executive Office...

Cet article est rÃ©servÃ© aux abonnÃ©s

Pour dÃ©bloquer l'article, ABONNEZ-VOUS !

Vous êtes déja client ? Log In

Latest news about OS Therapies Incorporated

OS Therapies to Develop Two Novel Cancer Treatment Candidates	09-13	MT
OS Therapies Announces Development of Two Novel Tunable Antibody Drug Conjugate-Based Therapeutic Candidates	09-13	CI
OS Therapies Announces Positive Efficacy and Safety Data for Ovarian Cancer Therapeutic Candidate Developed Based on Tunable Antibody Drug Conjugate Platform Using Proprietary Silicone Linker Platform in Preclinical Models	09-11	CI
OS Therapies Incorporated Announces Last Patient Enrolled in Ost-Her2 Osteosarcoma Phase 2B Clinical Trial Receives Last Treatment Dose	08-29	CI
OS Therapies Incorporated Appoints Borys Shor to Its Antibody Drug Conjugate Advisory Board	08-22	CI
OS Therapies Incorporated Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	08-14	CI
Transcript : Can-Fite BioPharma Ltd. - Special Call	08-10
OS Therapies Announces Osteosarcoma Scientific and Medical Advisory Board	08-06	CI
OS Therapies Incorporated Announces the Formation of A Patient Advocacy Advisory Board	08-02	CI
OS Therapies Incorporated has completed an IPO in the amount of $6.4 million.	07-31	CI
OS Therapies, Inc. Announces Positive Safety Data from Phase 1 Clinical Trial of OST-HER2 in HER2-Expressing Breast Cancer and in Preclinical Efficacy in Models of Breast Cancer	07-24	CI

Chart OS Therapies Incorporated

Duration

Period

More charts

OS Therapies Incorporated is a clinical-stage biopharmaceutical company. The Company is focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. It built a pipeline of product candidates targeting multiple indications for solid cancers. Its pipeline includes two drug technologies: OST-HER2 and OST-tADC. OST-HER2 is an off-the-shelf immunotherapy, which is a type of cancer treatment that helps oneâs immune system fight cancer, comprised of a genetically weakened and modified strain of Listeria monocytogenes, a species of bacteria that causes the infection listeriosis, that expresses HER2 peptides. OST-tADC is a tunable ADC with a plug-and-play platform that features tunable pH sensitive silicone linkers (SiLinkers). The payloads can include antibodies, chemotherapeutics, cytotoxins and potentially mRNA treatments directly into and in the vicinity of solid tumors.

Employees

Sector

Biotechnology & Medical Research

More about the company